Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

Heat maps of PSMA PET prostatic fossa recurrence in patients with recurrence limited to the prostate fossa (miTr N0 M0, n=127), pelvic nodal disease (miTr N1 M0, n=30), distant organs/extra-pelvic nodal disease (miTr N0 M1, n=32) and pelvic nodal plus distant organs/extra-pelvic nodal disease (miTr N1 M1, n=37). The yellow contour represents the RTOG CTV
News | Prostate Cancer
PSMA PET Highlights Need for Updated Prostate Cancer Therapy Guidelines

June 15, 2022 — Current guidelines used to plan salvage radiation treatments in patients with local recurrence of ...

Time June 15, 2022
arrow
At the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2022 Annual Meeting, GE Healthcare showcases cutting-edge solutions spanning the care continuum and enabling theranostics in prostate cancer
News | Prostate Cancer
GE Healthcare’s Total Molecular Imaging Solutions Enable Precision Health and Theranostics for Personalized Prostate Cancer Care

June 10, 2022 — GE Healthcare provides cutting-edge molecular imaging solutions that enable and increase access to ...

Time June 10, 2022
arrow
News | PET Imaging
Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

June 8, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 08, 2022
arrow
Craig Rogers, M.D., performed a robotic high intensity ultrasound case for Charles Rashid, 64, on April 8, 2022. Image courtesy of Henry Ford Health
News | Focused Ultrasound Therapy
Henry Ford Health First in Michigan to Offer Robotic High-intensity Focused Ultrasound for Prostate Cancer

May 12, 2022 — Henry Ford Health is the first in Michigan to offer Robotic High Intensity Focused Ultrasound (HIFU) for ...

Time May 12, 2022
arrow
Lumea, a global leader in integrated digital pathology solutions and Verily, an Alphabet precision health company, announced a strategic development partnership.
News | Digital Pathology
Verily and Lumea Announce Development Partnership

April 27, 2022 — Lumea, a global leader in integrated digital pathology solutions and Verily, an Alphabet precision ...

Time April 27, 2022
arrow
Over the past 15 years, public health authorities have downgraded recommendations for the prostate-specific antigen (PSA) test as a screening tool to reduce the overdiagnosis and overtreatment of men with low-grade prostate cancer.
News | Prostate Cancer
Less Prostate Cancer Screening Reduces Overdiagnosis but May Miss Aggressive Cases

April 25, 2022 — Over the past 15 years, public health authorities have downgraded recommendations for the prostate ...

Time April 25, 2022
arrow
Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug Application (IND) application for 177Lu-rhPSMA-10.1.
News | Prostate Cancer
Blue Earth Therapeutics Announces U.S. FDA Clearance for Investigational New Drug (IND) Application for 177Lu-rhPSMA-10.1

April 19, 2022 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time April 19, 2022
arrow
Prof. Dr. Samer Ezziddin, image courtesy of Thorsten Mohr/Saarland University
News | Prostate Cancer
New Radiotracer Yields Huge Increase in Accuracy of Localizing Prostate Cancer relapses

April 15, 2022 — Prostate cancer is the most common malignant tumor in men in Germany, with about 62,000 new cases ...

Time April 14, 2022
arrow
Quantitative analysis of pre-treatment PSMA PET/CT in a patient undergoing treatment with ¹⁷⁷Lutetium-PSMA-617/NOX66. Post-treatment PSMA PET/CT demonstrates reduced tumor volume and PSMA intensity. Images created by S Pathmanandavel and L Emmett, St Vincent's Hospital, Sydney, Australia.
News | PET-CT
New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients

April 11, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre ...

Time April 11, 2022
arrow
RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced artificial intelligence (AI) and computer vision solutions, announced a new tool for prostate MRI analysis.
News | Prostate Cancer
New AI Tool for Prostate MRI Analysis to Support PI-RADS Scoring

April 11, 2022 — RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced ...

Time April 11, 2022
arrow
Research in the March 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined data from the Ontario Cancer Registry from September 25, 2016 through September 26, 2020, to determine the impact of the COVID-19 pandemic on the number of new cancer cases detected.
News | Coronavirus (COVID-19)
New Research in JNCCN Measures Drop in Cancer Detection Due to the COVID-19 Pandemic

April 6, 2022 — Research in the March 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined ...

Time April 06, 2022
arrow
On Friday, April 1 at 2 p.m., the Milton and Caroll Petrie Department of Urology at Mount Sinai will host a ribbon cutting ceremony in Wagner Houses’ Community Plaza Ground, 451 East 120th Street, to celebrate the launch of the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit.
News | Prostate Cancer
Mount Sinai Health System Launches First-Ever Mobile Prostate Cancer Screening Unit in New York City

April 6, 2022 — On Friday, April 1 at 2 p.m., the Milton and Caroll Petrie Department of Urology at Mount Sinai will ...

Time April 06, 2022
arrow
The American College of Radiology (ACR) has selected 22 teams as the first cohort of the ACR Learning Network, a new initiative to improve diagnostic imaging through a learning health system approach.
News | Radiology Education
New ACR Initiative Harnesses Learning Health System Approach to Improve Diagnostic Imaging

April 5, 2022 — The American College of Radiology (ACR) has selected 22 teams as the first cohort of the ACR Learning ...

Time April 05, 2022
arrow
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports Advanced Accelerator Applications, a Novartis company, as a long-term supplier for the medical radioisotope component of the newly U.S. Food and Drug Administration (FDA) approved radiotherapeutic, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treat
News | Prostate Cancer
ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

March 28, 2022 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports ...

Time March 28, 2022
arrow
With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC)—the Society of Nuclear Medicine and Molecular Imaging (SNMMI) celebrates one of the greatest success stories in nuclear medicine history.
News | Prostate Cancer
SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical ...

Time March 23, 2022
arrow
A new study from Keck Medicine of USC finds that the incidence rate of metastatic prostate cancer has significantly increased for men 45 and older and coincides with recommendations against routine prostate cancer screenings.
News | Prostate Cancer
Metastatic Prostate Cancer on the Rise Since Decrease in Cancer Screenings

March 23, 2022 — A new study from Keck Medicine of USC finds that the incidence rate of metastatic prostate cancer has ...

Time March 23, 2022
arrow
Convergent will use NorthStar’s Ac-225 to radiolabel its lead asset, CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody, currently being investigated as a potential ground-breaking treatment for prostate cancer.
News | Prostate Cancer
NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

March 11, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time March 11, 2022
arrow
18F-rhPSMA-7.3 PET Photo courtesy of Blue Earth Diagnostics. General use: This 18F-rhPSMA-7.3 PET image shows prostate cancer spread beyond the prostate region. Technical use: This 18F-rhPSMA-7.3 PET image shows detection of recurrent prostate cancer in several retroperitoneal lymph nodes, as indicated by the green arrows.
News | Prostate Cancer
Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7.3

February 18, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time February 18, 2022
arrow
Benign Prostatic Hyperplasia (BPH) or prostate adenoma seen on MRI examination
News | Prostate Cancer
MRI-guided Radiotherapy Appears to Lead to Fewer Side Effects from Treatment for Prostate Cancer

February 17, 2022 — An interim analysis of an ongoing Phase III study from UCLA Jonsson Comprehensive Cancer Center ...

Time February 17, 2022
arrow
The American College of Radiology (ACR) reports that several states are considering breast, colon and lung cancer screening measures.
News | Radiology Imaging
States Advance Cancer Screening, Prior Authorization and Scope of Practice Legislation

The American College of Radiology (ACR) reports that several states are considering breast, colon and lung cancer ...

Time February 14, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now